U.S. Markets close in 1 hr 16 mins

Theravance price target raised to $48 from $38 at RW Baird

Baird raised its price target on Theravance following Elan's bid for 21% of certain royalty rights. The firm believe it signals management's desire to monetize assets and gives an indication of what those assets are worth. Shares are Outperform rated.